Sugi Predict

Sugi Predict / Targets / KDM2B

KDM2B

Lysine-specific demethylase 2B · Q8NHM5 · KDM2B on Sugi Atlas →

26,625 patent compounds predicted against KDM2B, 11,533 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1587744 SCHEMBL1587744 0.50 19/20
SCHEMBL467403 SCHEMBL467403 0.53 13/20
SCHEMBL467404 SCHEMBL467404 0.53 13/20
SCHEMBL467405 SCHEMBL467405 0.53 13/20
SCHEMBL287096 SCHEMBL287096 0.51 7/20
SCHEMBL1340897 SCHEMBL1340897 0.47 6/20
SCHEMBL977639 SCHEMBL977639 0.44 6/20
SCHEMBL977641 SCHEMBL977641 0.44 6/20
SCHEMBL974566 SCHEMBL974566 0.43 6/20
SCHEMBL974681 SCHEMBL974681 0.43 6/20
SCHEMBL977681 SCHEMBL977681 0.43 6/20
SCHEMBL1306302 SCHEMBL1306302 0.39 6/20
SCHEMBL1306304 SCHEMBL1306304 0.39 6/20
SCHEMBL1306307 SCHEMBL1306307 0.39 6/20
SCHEMBL1569134 SCHEMBL1569134 0.54 5/20
SCHEMBL978121 SCHEMBL978121 0.50 5/20
SCHEMBL1553746 SCHEMBL1553746 0.43 5/20
SCHEMBL1743034 SCHEMBL1743034 0.43 5/20
SCHEMBL1308395 SCHEMBL1308395 0.42 5/20
SCHEMBL1308398 SCHEMBL1308398 0.42 5/20

Clinical trials — most relevant to KDM2B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors PHASE2RECRUITING
Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum PHASE1/PHASE2RECRUITING
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia nanRECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Mechanisms of Immune Deficiency nanUNKNOWN
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KDM2B binder may also engage these)

ProteinNameSimilarity
Q6P1G2 — 1.000 Q6P1G2 →
Q8WML3 — 0.998 Q8WML3 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.996 landscape →
Q5TKR9 — 0.996 Q5TKR9 →
Q99PI5 — 0.995 Q99PI5 →
BRPF3 Bromodomain and PHD finger-containing protein 3 0.995 landscape →
A6QP06 — 0.995 A6QP06 →
Q640I9 — 0.995 Q640I9 →
Q92539 — 0.994 Q92539 →
Q9BQK8 — 0.994 Q9BQK8 →
KDM4B Lysine-specific demethylase 4B 0.994 landscape →
P58270 — 0.994 P58270 →
Q2PFD7 — 0.994 Q2PFD7 →
Q8BZ21 — 0.993 Q8BZ21 →
KAT6B Histone acetyltransferase KAT6B 0.993 landscape →
Q8BMD7 — 0.993 Q8BMD7 →
Q1LVC2 — 0.993 Q1LVC2 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.993 landscape →
Q63553 — 0.993 Q63553 →
Q9H329 — 0.993 Q9H329 →
P59997 — 0.993 P59997 →
KMT5B Histone-lysine N-methyltransferase KMT5B 0.992 landscape →
Q9NRR4 — 0.992 Q9NRR4 →
Q6EEF3 — 0.992 Q6EEF3 →
Q91ZP3 — 0.992 Q91ZP3 →
Q9VGA4 — 0.992 Q9VGA4 →
Q6NN85 — 0.992 Q6NN85 →
Q5HZJ0 — 0.992 Q5HZJ0 →
Q95Q98 — 0.992 Q95Q98 →
Q92784 — 0.992 Q92784 →